Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ambrx Biopharma Inc.AMAM · Entity 109604 | Director | September 01, 2023 | September 06, 2023 |
| ONCOSEC MEDICAL IncONCS · Entity 117092 | Director | August 23, 2021 | August 25, 2021 |
| SEELOS THERAPEUTICS, INC.SEEL · Entity 93662 | Director | January 04, 2024 | January 08, 2024 |
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | February 29, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ambrx Biopharma Inc.
Report date September 01, 2023 · Filed September 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
After 2023-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-01 · Grant · Acquired 125,000 · Balance 125,000 F1: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. F2: Represents the grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest in three successive equal annual installments beginning on September 1, 2024, subject to continuous service through such vesting date. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 70,833 |
Reported balance
After 2023-09-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-09-01 · Grant · Acquired 70,833 · Balance 70,833 F1: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. F3: Represents the grant of RSUs payable solely in Ordinary Shares of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the day immediately before the next annual general meeting, subject to continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer.
F2: Represents the grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest in three successive equal annual installments beginning on September 1, 2024, subject to continuous service through such vesting date.
F3: Represents the grant of RSUs payable solely in Ordinary Shares of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the day immediately before the next annual general meeting, subject to continuous service through such vesting date.
ONCOSEC MEDICAL Inc
Report date August 23, 2021 · Filed August 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2021-08-23 transaction · row 1
1 source rowRow 1 · 2021-08-23 · Purchase · Acquired 20,000 · Balance 20,000 |
SEELOS THERAPEUTICS, INC.
Report date January 04, 2024 · Filed January 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2034-01-04 | Direct | 1,666 |
Reported balance
After 2024-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-04 · Grant · Acquired 1,666 · Balance 1,666 F1: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter.
Skye Bioscience, Inc.
Report date February 29, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.56 · Expires 2034-03-01 | Direct | 35,000 |
Reported balance
After 2024-02-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-29 · Grant · Acquired 35,000 · Balance 35,000 F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ambrx Biopharma, Inc.
Report date March 07, 2024 · Filed March 07, 2024
Section 16 reporting ended · disclosed 2024-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-07 · Disposition to issuer · Disposed 17,857 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F3: The RSUs vest in three successive equal annual installments beginning on September 1, 2024, subject to continuous service through such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-07 · Disposition to issuer · Disposed 10,119 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F5: The RSUs vest on the earlier of (i) the one-year anniversary of the date of grant of September 1, 2023, and (ii) the day immediately before the next annual general meeting, subject to continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J.
F2: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock").
F3: The RSUs vest in three successive equal annual installments beginning on September 1, 2024, subject to continuous service through such vesting date.
F4: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU.
F5: The RSUs vest on the earlier of (i) the one-year anniversary of the date of grant of September 1, 2023, and (ii) the day immediately before the next annual general meeting, subject to continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2024 Filed Mar 7, 2024 17:36 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerRestricted Stock Units · Derivative | 10,119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-028177 · ownership.xml · derivative · entry 2 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,119 shares Expires not disclosed F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2 · derivative.exercise_price: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F5 · derivative.exercise_date: The RSUs vest on the earlier of (i) the one-year anniversary of the date of grant of September 1, 2023, and (ii) the day immediately before the next annual general meeting, subject to continuous service through such vesting date. F5 · derivative.expiration_date: The RSUs vest on the earlier of (i) the one-year anniversary of the date of grant of September 1, 2023, and (ii) the day immediately before the next annual general meeting, subject to continuous service through such vesting date. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:36 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerRestricted Stock Units · Derivative | 17,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-028177 · ownership.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,857 shares Expires not disclosed F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2 · derivative.exercise_price: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F3 · derivative.exercise_date: The RSUs vest in three successive equal annual installments beginning on September 1, 2024, subject to continuous service through such vesting date. F3 · derivative.expiration_date: The RSUs vest in three successive equal annual installments beginning on September 1, 2024, subject to continuous service through such vesting date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 06:24 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001516551-24-000027 · wk-form4_1709551460.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:45 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 1,666 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001104659-24-002385 · tm242318-3_4seq1.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,666 Underlying: Common Stock · 1,666 shares Expires 2034-01-04 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| November 06, 2023 Filed Nov 6, 2023 20:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 14,110 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001516551-23-000094 · wk-form4_1699320568.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,001 Underlying: Common Stock · 14,110 shares Expires 2033-08-25 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 17:52 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantOrdinary Shares | 70,833 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-046801 · ownership.xml · nonDerivative · entry 2 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,833 F1 · security: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. F3 · shares: Represents the grant of RSUs payable solely in Ordinary Shares of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the day immediately before the next annual general meeting, subject to continuous service through such vesting date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 17:52 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantOrdinary Shares | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-046801 · ownership.xml · nonDerivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 F1 · security: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. F2 · shares: Represents the grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest in three successive equal annual installments beginning on September 1, 2024, subject to continuous service through such vesting date. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 18:21 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 1,472,692 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001516551-23-000058 · wk-form4_1693347662.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,472,692 Underlying: Common Stock · 1,472,692 shares Expires 2033-08-25 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 19:19 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001136261-23-000006 · ownership.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-05 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on February 5, 2023, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 11:23 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.02 | $0.00 |
DisclosureSEC source: 0001516551-23-000012 · wf-form4_167328138631481.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-01-05 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 and the options will vest in equal monthly installments over the one year period beginning December 8, 2022. Read SEC document |
| May 26, 2022 Filed May 27, 2022 16:29 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | PurchaseCommon Stock | 35,000 | $0.60 | $20,965.00 |
DisclosureSEC source: 0001136261-22-000247 · ownership.xml · nonDerivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were acquired in multiple open market transactions at prices ranging from $0.5939 per share to $0.60 per share, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 20:04 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001136261-22-000019 · ownership.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-01-05 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on February 5, 2022, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 16:04 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantDirector Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001628280-21-018756 · wf-form4_163182260221131.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 150,000 shares Expires 2031-09-14 F1 · derivative.exercise_date: The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 16:08 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001136261-21-000208 · ownership.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 42,000 shares Expires 2031-09-01 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on September 1, 2022, and 1/36th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 17:31 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | PurchaseCommon Stock | 20,000 | $1.89 | $37,800.00 |
DisclosureSEC source: 0001493152-21-021268 · ownership.xml · nonDerivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 19:36 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001493152-21-015612 · ownership.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option will vest in equal quarterly installments over the next year. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001493152-20-017933 · ownership.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-09-14 F1 · derivative.exercise_date: The option vests quarterly over the next year. Read SEC document |
| August 07, 2020 Filed Aug 12, 2020 10:29 UTC | Skye Bioscience, Inc. EMBI · Entity 8098 | GrantDirector Option Grant (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001640334-20-002044 · primary_doc.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-08-07 F1 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over two years. Read SEC document |
| May 29, 2020 Filed Jun 3, 2020 21:12 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001493152-20-010508 · ownership.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-04-14 F1 · date: The option grant was approved by the Issuer's Compensation Committee on April 14, 2020, subject to stockholder approval of an amendment to the Issuer's 2011 Incentive Plan to increase the number of authorized shares. The Issuer's stockholders approved the plan amendment on May 29, 2020. F2 · derivative.exercise_date: The option was 25% vested on April 14, 2020, and the remainder vests quarterly over the next three years. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 18:15 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001493152-19-006033 · ownership.xml · derivative · entry 1 DALESANDRO MARGARET · CIK 0001208853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-04-24 F1 · shares: Vesting will occur in 12 equal monthly increments, with the first 1/12th vesting on the first month anniversary of the Grant Date pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.